Author Archives: Marisa Wexler MS

FDA Paves Way for Phase 2 Testing of EHP-101 for Scleroderma

The U.S. Food and Drug Administration (FDA) has cleared an application from Emerald Health Pharmaceuticals that paves the way to begin a Phase 2 clinical trial testing EHP-101 in people with scleroderma. EHP-101 is an oral therapy based on cannabidiol (CBD), one of the main components of cannabis and…